References
- Davies H, Bignell GR, Cox C, . Mutations of the BRAF gene in human cancer. Nature 2002;417:949–954.
- Halilovic E, Solit DB. Therapeutic strategies for inhibiting oncogenic BRAF signaling. Curr Opin Pharmacol 2008;8:419–426.
- Tiacci E, Trifonov V, Schiavoni G, . BRAF mutations in hairy-cell leukemia. N Engl J Med 2011;364:2305–2315.
- Badalian-Very G, Vergilio JA, Degar BA, . Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010;116:1919–1923.
- Flaherty KT, Yasothan U, Kirkpatrick P. Vemurafenib. Nat Rev Drug Discov 2011;10:811–812.
- Tefferi A, Vardiman JW. Classification and diagnosis of myelo-proliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14–22.
- Vardiman JW, Thiele J, Arber DA, . The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937–951.
- Sapio MR, Posca D, Troncone G, . Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol 2006;154:341–348.
- Arcaini L, Zibellini S, Boveri E, . The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood 2012;119:188–191.
- Blombery P, Wong SQ, Hewitt CA, . Detection of BRAF mutations in patients with hairy cell leukemia and related lymphoproliferative disorders. Haematologica 2011 Dec 1. [Epub ahead of print]
- Chapman MA, Lawrence MS, Keats JJ, . Initial genome sequencing and analysis of multiple myeloma. Nature 2011;471:467–472.
- Pardanani A, Tefferi A. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011;365:961; author reply 961–962.
- Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 2011;29:573–582.